The Wu-Tang Clan rapper has recorded a video smackdown of pharma bad boy Shkreli.» Read More
The Zika virus should not cause Americans to be "unduly alarmed just yet," says infectious disease expert Paul Roepe.
Gilead Sciences on Friday that John Milligan, currently president and chief operating officer, will be promoted to CEO and appointed to the board of directors.
Amgen boosted guidance after it beat on fourth-quarter earnings, helped by sales of its rheumatoid arthritis drug Enbrel.
Massachusetts Attorney General Maura Healey explains why it's worth investigating drug pricing and Gilead's practices.
The rap-fueled beef with Ghostface Killah was recorded while the pharma exec Martin Shkreli is free on $5 million bond.
Health care is one of the biggest drags on the market right now because of the moves lower in biotech stocks. CNBC's Meg Tirrell looks ahead to biotech earnings out next week. The FMHR traders and Kate Moore, JPMorgan Private Bank chief investment strategist, discuss.
Regulators warn that new Theranos lab in California is unsafe for patients, company says it's taking corrective action. CNBC's Meg Tirrell explains.
A safe vaccine for the Zika virus will likely not be available this year or the following year, an NIH official said Thursday.
Severin Schwan, CEO of Roche, discusses his company's full year results, which came in below expectations.
The rapid spread of the zika virus has spurred the hunt for a cure, but the financial incentive and likely length of time for a vaccine are unclear.
Drugmaker Roche on Thursday reported full-year earnings and a dividend slightly below forecasts and said it expected sales to grow low- to mid-single digit in 2016.
The "Fast Money" traders give their final trades of the day.
Massachusetts AG Maura Healey said the costs of two drugs "may constitute an unfair trade practice in violation of Massachusetts law."
Scientists developed a device to prevent implanted insulin-producing cells from being attacked by the immune system for six months.
CNBC's Meg Tirrell breaks down the quarterly numbers on Biogen and Novartis.
Biogen's quarterly profit breezed past Wall Street's estimates, driven by higher demand for its key oral multiple sclerosis drug Tecfidera.
Cathrin Petty, head of EMEA healthcare at JP Morgan, says 2016 will be a pivotal year for the health care industry due to new product launches and approvals, as well as commercial headwinds.
CNBC correspondent Julia Chatterley reports on Novartis' 4th quarter net income of $2.7 billion, which was below forecasts.
Xavier Rolet, CEO of the London Stock Exchange, talks about the success pharma and health care companies have had raising capital in the U.K.
CNBC's Meg Tirrell highlights the increasingly popular political stance against increasing drug prices.
Get the best of CNBC in your inbox